Acesis Holdings ^{Withdrawn, Nasdaq: ACSB}

Acesis Holdings Corporation together with its wholly-owned subsidiaries, Acesis Biomed Limited, a company incorporated in England and Wales (“Acesis UK”), and Acesis Biomed US, Inc., a Colorado corporation (“ABI”), is an emerging, pre-phase 1 (first-in-man “FIM”) clinical, biotechnology company focused on men’s health. Since the incorporation of ABI in the State of Colorado on March 11, 2015, we have been developing novel treatments for low testosterone levels in males (“Low–T”) known as T-deficiency or male hypogonadism. Our business model is to develop non-steroid innovative proprietary product candidates that transform the treatment of men with Low-T. Our product candidate pipeline is based on the discoveries of our co-founder Dr. Papadopoulos, a recognized expert in the steroid biochemistry field. Dr. Papadopoulos is currently the Dean of the University of Southern California (“USC”) School of Pharmacy, John Stauffer Dean’s Chair in Pharmaceutical Sciences & Professor of Pharmacology and Pharmaceutical Sciences. The Company’s mission is to transform the treatment of Low–T in males (also known as hypogonadism) using non-hormonal, orally administered peptide therapeutics and thereby expanding the therapeutic choices that health care providers and patients have in a market currently dominated by non-oral options.